ROIV · Roivant Sciences Ltd. · Earnings Call Transcripts & Audio
$36.57
+0.00 (+0.00%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$25.86B
Shares
722.32M
Volume · Sep 30
5.28M
Avg daily vol (3M)
7.03M
Roivant Sciences Ltd. Earnings Call Transcripts
Quarterly earnings calls for Roivant Sciences Ltd. (ROIV), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼10.4%
$12.53M
−$291.59M
'23 Q2
22-11-14
▼29.9%
$17.05M
−$352.01M
'23 Q3
23-02-01
▼125.7%
$
−$33.62M
'23 Q4
23-06-28
▲400.7%
$21.62M
−$291.82M
'24 Q1
23-08-14
▼70.9%
$3.65M
−$304.33M
'24 Q2
23-11-13
▼8.7%
$15.56M
$5.10B
'24 Q3
24-02-13
·
$
−$151.12M
'24 Q4
24-05-30
▼63.1%
$7.99M
$95.30M
'25 Q1
24-08-08
▲22.7%
$4.47M
−$230.18M
'25 Q2
24-11-12
▼42.1%
$9.02M
$169.38M
'25 Q3
25-02-10
·
$7.57M
−$206.47M
'25 Q4
25-05-29
▼72.8%
$2.17M
−$223.35M
'26 Q1
25-08-11
▼64.9%
$1.57M
−$113.52M
'26 Q2
25-11-10
▼77.8%
$2.00M
−$265.89M
'26 Q3
26-02-06
▼66.7%
$2.52M
$302.99M
'26 Q4
26-05-20
LATEST
▼33.5%
$1.44M
−$189.84M
'27 Q1
26-08-06
Conference
Investor event
2026-09-08
Roivant Sciences Ltd. (ROIV) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY27 · Q1
2026-08-06
Roivant Sciences Ltd. (ROIV) Q1 2027 Earnings Call Transcript
Confident tone
Pipeline catalysts and second-half data
IMVT-1402 FcRn program (Graves, MG, CIDP)
Cutaneous sarcoidosis phase 3
Revenue
$1.44M
▼ 33.5% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Roivant Sciences Ltd. (ROIV) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Roivant Sciences Ltd. (ROIV) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-29
Roivant Sciences Ltd. (ROIV) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q4
2026-05-20
Roivant Sciences Ltd. (ROIV) Q4 2026 Earnings Call
Confident tone
Mosliciguat PH-ILD Phase 2B
Period 2 randomized withdrawal readout
Commercial launch execution
Revenue
$2.52M*
▼ 66.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY26 · Q3
2026-02-06
Roivant Sciences Ltd. (ROIV) Q3 2026 Earnings Call Transcript
Confident tone
Competitive landscape vs Argenix in Graves/TED
BREPO Phase 2 data in cutaneous sarcoidosis
Graves' disease program and launch readiness
Revenue
$2.00M
▼ 77.8% YoY Diluted EPS
$-0.38
▼ 265.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2025-11-10
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Confident tone
TED and competitive landscape
Batoclimab/1402 in Graves' disease
Brepocitinib VALOR data in DM
Revenue
$1.57M
▼ 64.9% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2025-08-11
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call
Revenue
$2.17M
▼ 72.8% YoY Diluted EPS
$-0.33
▼ 375% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-05-29
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Confident tone
Batoclimab / TED program failure
Period 2 randomized withdrawal and placebo
1402 / DGTRA open-label data
Revenue
$7.57M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-02-10
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
Confident tone
Brepocitinib registrational programs and upcoming milestones
Pipeline catalysts and 2026 catalysts
Graves' disease launch and competitive landscape
Revenue
$9.02M
▼ 42.1% YoY Diluted EPS
$0.23
▼ 96.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2024-11-12
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Confident tone
Graves' disease and batoclimab/1402 strategy
IMVT-1402 across multiple indications
Brepocitinib VALOR data in dermatomyositis
Revenue
$4.47M
▲ 22.7% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2024-08-08
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
Revenue
$7.99M
▼ 63.1% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-05-30
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-02-13
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Confident tone
Indication selection strategy for brepasitinib
Catalysts and milestones in 2025
Pipeline breadth and BD activity
Revenue
$15.56M
▼ 8.7% YoY Diluted EPS
$6.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2023-11-13
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Revenue
$3.65M
▼ 70.9% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2023-08-14
Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript
Revenue
$21.62M
▲ 400.7% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-06-28
Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript
Revenue
$*
▼ 125.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-02-01
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
Revenue
$17.05M
▼ 29.9% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2022-11-14
Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript
Revenue
$12.53M
▼ 10.4% YoY Diluted EPS
$-0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-08-15
Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript
Revenue
$4.32M
▼ 44.2% YoY Diluted EPS
$-0.48
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-06-28
Roivant Sciences Ltd. (ROIV) Q4 2022 Earnings Call Transcript
Revenue
$9.22M*
▼ 39.1% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-02-14
Roivant Sciences Ltd. (ROIV) Q3 2022 Earnings Call Transcript
Revenue
$24.34M
▲ 323.3% YoY Diluted EPS
$-0.41
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2021-11-15
Roivant Sciences Ltd. (ROIV) Q2 2022 Earnings Call Transcript
Revenue
$13.99M
▲ 957.2% YoY Diluted EPS
$-0.32
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2021-09-21
Roivant Sciences Ltd. (ROIV) Q1 2022 Earnings Call Transcript
Revenue
$7.74M
▲ 390.8% YoY Diluted EPS
$-0.13
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2020-09-30
Roivant Sciences Ltd. (ROIV) Q2 2021 Earnings Call Transcript
Revenue
$1.32M
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts
CIK
1635088
CUSIP
G76279101
13F (30d)
10 filings
10 filers
Visit website
Investor relations